Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.73 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.73 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.73 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 6/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11190435 | 1.00 | LMNA (0.73) | LMNASLC22A6SLC22A8SLC22A11PTGS2 | |
| SCHEMBL11190440 | 1.00 | LMNA (0.73) | LMNASLC22A6SLC22A8SLC22A11PTGS2 | |
| SCHEMBL25938280 | 0.88 | LMNA (0.58) | LMNASLC22A6SLC22A8SLC22A11PTGS2 | |
| Ceftezole SCHEMBL147529 | 0.87 | LMNA (0.79) | LMNASLC22A6SLC22A8SLC22A11PTGS2 | |
| Ceftezole SCHEMBL11033790 | 0.87 | LMNA (0.79) | LMNASLC22A6SLC22A8SLC22A11PTGS2 | |
| Ceftezole SCHEMBL11033793 | 0.87 | LMNA (0.79) | LMNASLC22A6SLC22A8SLC22A11PTGS2 | |
| SCHEMBL11346639 | 0.86 | LMNA (0.73) | LMNASLC22A6SLC22A8SLC22A11PTGS2 | |
| Ceftezole SCHEMBL2259026 | 0.86 | LMNA (0.78) | LMNASLC22A6SLC22A8SLC22A11PTGS2 | |
| Cefazolin SCHEMBL11031717 | 0.85 | LMNA (1.00) | LMNASLC22A6SLC22A8SLC22A11PTGS2 | |
| Cefazolin SCHEMBL16072809 | 0.85 | LMNA (1.00) | LMNASLC22A6SLC22A8SLC22A11PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119096144-A | Rapid diagnostic test for antibiotic resistance and methods of use and preparation thereof | 拜奥普诊断公司 | 2024-12-06 | — | — | CN | disclosed |
| EP-4469800-A1 | RAPID DIAGNOSTIC TEST FOR ANTIBIOTIC RESISTANCE, AND METHODS OF USE AND METHODS OF MAKING THEREOF | Bioamp Diagnostics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023147071-A9 | RAPID DIAGNOSTIC TEST FOR ANTIBIOTIC RESISTANCE, AND METHODS OF USE AND METHODS OF MAKING THEREOF | BIOAMP DIAGNOSTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2023147071-A9 | RAPID DIAGNOSTIC TEST FOR ANTIBIOTIC RESISTANCE, AND METHODS OF USE AND METHODS OF MAKING THEREOF | BIOAMP DIAGNOSTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2023147071-A1 | RAPID DIAGNOSTIC TEST FOR ANTIBIOTIC RESISTANCE, AND METHODS OF USE AND METHODS OF MAKING THEREOF | BIOAMP DIAGNOSTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147071-A1 | RAPID DIAGNOSTIC TEST FOR ANTIBIOTIC RESISTANCE, AND METHODS OF USE AND METHODS OF MAKING THEREOF | BIOAMP DIAGNOSTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20220177947-A1 | Compounds to Identify Beta-Lactamases, and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-09 | — | — | US | disclosed |
| WO-2021041583-A1 | COMPOUNDS TO IDENTIFY BETA-LACTAMASES, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177947-A1 | Compounds to Identify Beta-Lactamases, and Methods of Use Thereof | GUSB, GLB1, MGAM | LMNA 403/4885SLC22A6 1406/4885SLC22A8 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.